Literature DB >> 33691275

Sociodemographic Factors Associated With Rapid Relapse in Triple-Negative Breast Cancer: A Multi-Institution Study.

Sarah Asad1, Carlos H Barcenas2, Richard J Bleicher3, Adam L Cohen4, Sara H Javid5, Ellis G Levine6, Nancy U Lin7, Beverly Moy8, Joyce Niland9, Antonio C Wolff10, Michael J Hassett7, Daniel G Stover1.   

Abstract

BACKGROUND: Triple-negative breast cancer (TNBC) accounts for disproportionately poor outcomes in breast cancer, driven by a subset of rapid-relapse TNBC (rrTNBC) with marked chemoresistance, rapid metastatic spread, and poor survival. Our objective was to evaluate clinicopathologic and sociodemographic features associated with rrTNBC.
METHODS: We included patients diagnosed with stage I-III TNBC in 1996 through 2012 who received chemotherapy at 1 of 10 academic cancer centers. rrTNBC was defined as a distant metastatic recurrence event or death ≤24 months after diagnosis. Features associated with rrTNBC were included in a multivariable logistic model upon which backward elimination was performed with a P<.10 criterion, with a final multivariable model applied to training (70%) and independent validation (30%) cohorts.
RESULTS: Among all patients with breast cancer treated at these centers, 3,016 fit the inclusion criteria. Training cohort (n=2,112) bivariable analyses identified disease stage, insurance type, age, body mass index, race, and income as being associated with rrTNBC (P<.10). In the final multivariable model, rrTNBC was significantly associated with higher disease stage (adjusted odds ratio for stage III vs I, 16.0; 95% CI, 9.8-26.2; P<.0001), Medicaid/indigent insurance, lower income (by 2000 US Census tract), and younger age at diagnosis. Model performance was consistent between the training and validation cohorts. In sensitivity analyses, insurance type, low income, and young age were associated with rrTNBC among patients with stage I/II but not stage III disease. When comparing rrTNBC versus late relapse (>24 months), we found that insurance type and young age remained significant.
CONCLUSIONS: Timing of relapse in TNBC is associated with stage of disease and distinct sociodemographic features, including insurance type, income, and age at diagnosis.

Entities:  

Mesh:

Year:  2021        PMID: 33691275      PMCID: PMC8564718          DOI: 10.6004/jnccn.2020.7659

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  31 in total

1.  Triple-negative breast cancer: clinical features and patterns of recurrence.

Authors:  Rebecca Dent; Maureen Trudeau; Kathleen I Pritchard; Wedad M Hanna; Harriet K Kahn; Carol A Sawka; Lavina A Lickley; Ellen Rawlinson; Ping Sun; Steven A Narod
Journal:  Clin Cancer Res       Date:  2007-08-01       Impact factor: 12.531

2.  The impact of obesity on receipt of adjuvant chemotherapy for breast cancer in the National Comprehensive Cancer Network (NCCN) centers.

Authors:  A M Brewster; C Etzel; R Zhou; Y Wong; S Edge; D W Blayney; J Wilson; C Hudis; R Ottesen; M E Hughes; J C Weeks; R L Theriault
Journal:  Breast Cancer Res Treat       Date:  2011-08-02       Impact factor: 4.872

3.  Socioeconomic inequalities in attending the mass screening for breast cancer in the south of the Netherlands--associations with stage at diagnosis and survival.

Authors:  M J Aarts; A C Voogd; L E M Duijm; J W W Coebergh; W J Louwman
Journal:  Breast Cancer Res Treat       Date:  2011-02-03       Impact factor: 4.872

4.  Tumour evolution inferred by single-cell sequencing.

Authors:  Nicholas Navin; Jude Kendall; Jennifer Troge; Peter Andrews; Linda Rodgers; Jeanne McIndoo; Kerry Cook; Asya Stepansky; Dan Levy; Diane Esposito; Lakshmi Muthuswamy; Alex Krasnitz; W Richard McCombie; James Hicks; Michael Wigler
Journal:  Nature       Date:  2011-03-13       Impact factor: 49.962

5.  The influence of race, ethnicity, and individual socioeconomic factors on breast cancer stage at diagnosis.

Authors:  Paula M Lantz; Mahasin Mujahid; Kendra Schwartz; Nancy K Janz; Angela Fagerlin; Barbara Salem; Lihua Liu; Dennis Deapen; Steven J Katz
Journal:  Am J Public Health       Date:  2006-10-31       Impact factor: 9.308

6.  The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression-Based Meta-Analysis.

Authors:  Daniel G Stover; Jonathan L Coloff; William T Barry; Joan S Brugge; Eric P Winer; Laura M Selfors
Journal:  Clin Cancer Res       Date:  2016-06-21       Impact factor: 12.531

7.  Trends in area-socioeconomic and race-ethnic disparities in breast cancer incidence, stage at diagnosis, screening, mortality, and survival among women ages 50 years and over (1987-2005).

Authors:  Sam Harper; John Lynch; Stephen C Meersman; Nancy Breen; William W Davis; Marsha C Reichman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-01       Impact factor: 4.254

8.  Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.

Authors:  Peter Schmid; Sylvia Adams; Hope S Rugo; Andreas Schneeweiss; Carlos H Barrios; Hiroji Iwata; Véronique Diéras; Roberto Hegg; Seock-Ah Im; Gail Shaw Wright; Volkmar Henschel; Luciana Molinero; Stephen Y Chui; Roel Funke; Amreen Husain; Eric P Winer; Sherene Loi; Leisha A Emens
Journal:  N Engl J Med       Date:  2018-10-20       Impact factor: 91.245

9.  Time to adjuvant chemotherapy for breast cancer in National Comprehensive Cancer Network institutions.

Authors:  Jonathan L Vandergrift; Joyce C Niland; Richard L Theriault; Stephen B Edge; Yu-Ning Wong; Loretta S Loftus; Tara M Breslin; Clifford A Hudis; Sara H Javid; Hope S Rugo; Samuel M Silver; Eva M Lepisto; Jane C Weeks
Journal:  J Natl Cancer Inst       Date:  2012-12-21       Impact factor: 13.506

10.  Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study.

Authors:  Ines Vaz-Luis; Rebecca A Ottesen; Melissa E Hughes; Rizvan Mamet; Harold J Burstein; Stephen B Edge; Ana M Gonzalez-Angulo; Beverly Moy; Hope S Rugo; Richard L Theriault; Jane C Weeks; Eric P Winer; Nancy U Lin
Journal:  J Clin Oncol       Date:  2014-06-02       Impact factor: 44.544

View more
  3 in total

1.  A Novel Risk-Scoring System to Identify the Potential Population Benefiting From Adjuvant Chemotherapy for Node-Negative TNBC Patients With Tumor Size Less Than 1 cm.

Authors:  Yijun Li; Rulan Ma; Heyan Chen; Shengyu Pu; Peiling Xie; Jianjun He; Huimin Zhang
Journal:  Front Oncol       Date:  2022-06-23       Impact factor: 5.738

2.  Socioeconomic and Surgical Disparities are Associated with Rapid Relapse in Patients with Triple-Negative Breast Cancer.

Authors:  Samilia Obeng-Gyasi; Sarah Asad; James L Fisher; Saurabh Rahurkar; Daniel G Stover
Journal:  Ann Surg Oncol       Date:  2021-02-14       Impact factor: 4.339

3.  Cannabidiol loaded extracellular vesicles sensitize triple-negative breast cancer to doxorubicin in both in-vitro and in vivo models.

Authors:  Nilkumar Patel; Nagavendra Kommineni; Sunil Kumar Surapaneni; Anil Kalvala; Xuegang Yaun; Aragaw Gebeyehu; Peggy Arthur; Leanne C Duke; Sara B York; Arvind Bagde; David G Meckes; Mandip Singh
Journal:  Int J Pharm       Date:  2021-07-27       Impact factor: 6.510

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.